论文部分内容阅读
目的观察抗幽门螺杆菌(Hp)治疗对乙型肝炎后肝硬化合并Hp感染患者血清肝功能、IL-8、IL-6的影响。方法选择101例乙型肝炎后肝硬化合并Hp感染患者,随机分成两组。对照组给予常规治疗,治疗组在常规治疗基础上加用抗Hp药物(雷贝拉唑肠溶胶囊,阿莫西林胶囊,克林霉素,枸橼酸铋钾)。检测两组患者治疗前及停药4周后血清中ALT,AST,STB,IL-8,IL-6水平。结果两组患者治疗前血清肝功能、IL-6、IL-8水平均较高,组间差异无统计学意义(P>0.05)。治疗后1个月复查血清肝功能、IL-6、IL-8水平,明显低于治疗前,差异有统计学意义(P<0.01)。治疗组患者肝功能及IL-6,IL-8水平较对照组下降更显著,差异有统计学意义(P<0.05)。结论抗Hp治疗可以降低乙型肝炎后肝硬化合并Hp感染患者血清中IL-8,IL-6水平,更好地保护乙型肝炎后肝硬化患者的肝功能。
Objective To observe the effects of anti-Helicobacter pylori (Hp) treatment on serum liver function, IL-8 and IL-6 in patients with post-hepatitis B cirrhosis complicated with Hp infection. Methods 101 cases of hepatitis B patients with cirrhosis and Hp infection were randomly divided into two groups. The control group was given routine treatment. The treatment group was given anti-Hp drug (rabeprazole enteric-coated capsules, amoxicillin capsules, clindamycin, bismuth potassium citrate) on the basis of routine treatment. Serum levels of ALT, AST, STB, IL-8 and IL-6 were measured before treatment and 4 weeks after discontinuation in both groups. Results Before treatment, serum liver function, IL-6 and IL-8 levels were significantly higher in both groups, with no significant difference between the two groups (P> 0.05). The levels of serum liver function, IL-6 and IL-8 in the 1 month after treatment were significantly lower than those before treatment (P <0.01). The liver function and the levels of IL-6 and IL-8 in treatment group were significantly lower than those in control group (P <0.05). Conclusion Anti-Hp treatment can reduce the levels of IL-8 and IL-6 in the serum of patients with cirrhosis and Hp infection after hepatitis B, and can better protect the liver function of patients with cirrhosis after hepatitis B infection.